Clinical trial

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

NCT01251835

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Sitaxsentan alone Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Sitaxsentan Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Rifampin Normalized identity: rifampinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2010-12-01

PhasePHASE1

Conditions

Pulmonary Arterial Hypertensionverified · MONDO: pulmonary arterial hypertension

Interventions

Sitaxsentan aloneDRUG

SitaxsentanDRUG

RifampinDRUG · verified · RxNorm: rifampin

Sponsors & collaborators

Pfizerlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01251835 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.